CSPC PHARMA's SYH2069 injection has been approved to conduct clinical trials in the United States
CSPC PHARMA (01093.HK) announced that the GLP-1/GIP receptor dual agonist peptide injection developed by the group (SYH2069 injection) has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. The approved clinical indication is weight management for individuals with obesity or overweight combined with at least one weight-related comorbidity
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments